Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jenkins

Showing results (781-790 of 799) with videos related to

Pageof 80
Sort By:
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Scientific Reports|May 11, 2018
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21Quinn T Ostrom, Ben Kinnersley, Margaret R Wrensch, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Plos One|August 17, 2016
Assessing the Cost of Global Biodiversity and Conservation KnowledgeDiego Juffe-Bignoli, Thomas M Brooks, Stuart H M Butchart, et al.
Neuro-Oncology Practice|May 14, 2026
Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based surveyFrancis Zerd, Lateef A Odukoya, Beverly Cheserem, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Nature|April 28, 2022
A global reptile assessment highlights shared conservation needs of tetrapodsNeil Cox, Bruce E Young, Philip Bowles, et al.
Pageof 80

Showing results (781-790 of 799) with videos related to

Sort By:
Pageof 80
Cell Reports. Medicine|June 21, 2023
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomasMarkus Bredel, Lluís Espinosa, Hyunsoo Kim, et al.
Scientific Reports|May 11, 2018
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21Quinn T Ostrom, Ben Kinnersley, Margaret R Wrensch, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Plos One|August 17, 2016
Assessing the Cost of Global Biodiversity and Conservation KnowledgeDiego Juffe-Bignoli, Thomas M Brooks, Stuart H M Butchart, et al.
Neuro-Oncology Practice|May 14, 2026
Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based surveyFrancis Zerd, Lateef A Odukoya, Beverly Cheserem, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Nature|April 28, 2022
A global reptile assessment highlights shared conservation needs of tetrapodsNeil Cox, Bruce E Young, Philip Bowles, et al.
Pageof 80